Lymphopenia Tied to Risk of Infection After Radiotherapy
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
Cancer patients with a SARS-CoV-2 infection before vaccination had a higher risk of death after a breakthrough infection.
The median cancer-specific survival was 56.5 months.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Iodine concentration and Hounsfield units were associated with treatment response and survival.
The risk of death from any cause was higher with degarelix.
The seroconversion rate was 92%.
It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.
Experts outline benefits and detriments of COVID-19 vaccine mandates.